Company intelligence / Profile preview

Bio-Thera Solutions, Ltd.

Ownership: Public · 688177
Employees: ~1167
Development stage: Commercial

Overview

The company has multiple approved products including QLETLI® (adalimumab biosimilar), POBEVCY® (bevacizumab biosimilar), TOFIDENCE™, BETAGRIN®, and Avzivi® (bevacizumab-tnjn)

Therapeutic areas: GastroenterologyCardiovascularRheumatologyOphthalmologyImmunologyDermatologyOncology
Modalities: Antibody drugsbiosimilarsbi-functional fusion proteins
Industry: Biotech

Drug pipeline

37 assets

Starjemza

Approved

36 more assets in the full pipeline.

Request access →

Partnerships

STADA (for BAT2506)

Beyond the preview

Go deeper on Bio-Thera Solutions, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-Thera Solutions, Ltd..

Explore the full profile